Selected research
Market Structure
Global Platinum Anti-tumor Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Platinum Anti-tumor Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Platinum Anti-tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Platinum Anti-tumor Drugs include Teva, Sun Pharma, Sanofi, Novartis, Pfizer, Hengrui Medicine, Yi Bai Pharmaceutical, Viatris and SK Chemicals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Platinum Anti-tumor Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Platinum Anti-tumor Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Platinum Anti-tumor Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Platinum Anti-tumor Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Platinum Anti-tumor Drugs Segment by Company
Teva
Sun Pharma
Sanofi
Novartis
Pfizer
Hengrui Medicine
Yi Bai Pharmaceutical
Viatris
SK Chemicals
Qilu Pharmaceutical
Dr Reddy's Laboratories
Debiopharm
ASK Pharma
Accord Healthcare
Platinum Anti-tumor Drugs Segment by Type
Oxaliplatin
Carboplatin
Cisplatin
Other
Platinum Anti-tumor Drugs Segment by Application
Ovarian Cancer
Lung Cancer
Colorectal Cancer
Other
Platinum Anti-tumor Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum Anti-tumor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Platinum Anti-tumor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum Anti-tumor Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Platinum Anti-tumor Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Platinum Anti-tumor Drugs industry.
Chapter 3: Detailed analysis of Platinum Anti-tumor Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Platinum Anti-tumor Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oxaliplatin
- Carboplatin
- Cisplatin
- Other
Applications
- Ovarian Cancer
- Lung Cancer
- Colorectal Cancer
- Other
Companies covered
- Teva
- Sun Pharma
- Sanofi
- Novartis
- Pfizer
- Hengrui Medicine
- Yi Bai Pharmaceutical
- Viatris
- SK Chemicals
- Qilu Pharmaceutical
- Dr Reddy's Laboratories
- Debiopharm
- ASK Pharma
- Accord Healthcare
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Platinum Anti-tumor Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Oxaliplatin
- 1.2.3 Carboplatin
- 1.2.4 Cisplatin
- 1.2.5 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Platinum Anti-tumor Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Ovarian Cancer
- 1.3.3 Lung Cancer
- 1.3.4 Colorectal Cancer
- 1.3.5 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Platinum Anti-tumor Drugs Growth Trends by Region
- 1.5.1 Global Platinum Anti-tumor Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Platinum Anti-tumor Drugs Market Size by Region (2021-2026)
- 1.5.3 Platinum Anti-tumor Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Platinum Anti-tumor Drugs Market Dynamics
- 2.1 Platinum Anti-tumor Drugs Industry Trends
- 2.2 Platinum Anti-tumor Drugs Industry Drivers
- 2.3 Platinum Anti-tumor Drugs Industry Opportunities and Challenges
- 2.4 Platinum Anti-tumor Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Platinum Anti-tumor Drugs Revenue by Company (2021-2026)
- 3.2 Global Platinum Anti-tumor Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Platinum Anti-tumor Drugs Key Company Head office and Area Served
- 3.4 Global Platinum Anti-tumor Drugs Company, Product Type & Application
- 3.5 Global Platinum Anti-tumor Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Platinum Anti-tumor Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Platinum Anti-tumor Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Platinum Anti-tumor Drugs Tier 1, Tier 2, and Tier 3
4 Platinum Anti-tumor Drugs Market by Type
- 4.1 Global Platinum Anti-tumor Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Platinum Anti-tumor Drugs Market Size by Type (2021-2032)
- 4.3 Global Platinum Anti-tumor Drugs Market Size Share by Type (2021-2032)
5 Platinum Anti-tumor Drugs Market by Application
- 5.1 Global Platinum Anti-tumor Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Platinum Anti-tumor Drugs Market Size by Application (2021-2032)
- 5.3 Global Platinum Anti-tumor Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Teva
- 6.1.1 Teva Company Information
- 6.1.2 Teva Business Overview
- 6.1.3 Teva Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Teva Platinum Anti-tumor Drugs Product Portfolio
- 6.1.5 Teva Recent Developments
- 6.2 Sun Pharma
- 6.2.1 Sun Pharma Company Information
- 6.2.2 Sun Pharma Business Overview
- 6.2.3 Sun Pharma Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Sun Pharma Platinum Anti-tumor Drugs Product Portfolio
- 6.2.5 Sun Pharma Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sanofi Platinum Anti-tumor Drugs Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Novartis Platinum Anti-tumor Drugs Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pfizer Platinum Anti-tumor Drugs Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Hengrui Medicine
- 6.6.1 Hengrui Medicine Company Information
- 6.6.2 Hengrui Medicine Business Overview
- 6.6.3 Hengrui Medicine Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio
- 6.6.5 Hengrui Medicine Recent Developments
- 6.7 Yi Bai Pharmaceutical
- 6.7.1 Yi Bai Pharmaceutical Company Information
- 6.7.2 Yi Bai Pharmaceutical Business Overview
- 6.7.3 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
- 6.7.5 Yi Bai Pharmaceutical Recent Developments
- 6.8 Viatris
- 6.8.1 Viatris Company Information
- 6.8.2 Viatris Business Overview
- 6.8.3 Viatris Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Viatris Platinum Anti-tumor Drugs Product Portfolio
- 6.8.5 Viatris Recent Developments
- 6.9 SK Chemicals
- 6.9.1 SK Chemicals Company Information
- 6.9.2 SK Chemicals Business Overview
- 6.9.3 SK Chemicals Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 SK Chemicals Platinum Anti-tumor Drugs Product Portfolio
- 6.9.5 SK Chemicals Recent Developments
- 6.10 Qilu Pharmaceutical
- 6.10.1 Qilu Pharmaceutical Company Information
- 6.10.2 Qilu Pharmaceutical Business Overview
- 6.10.3 Qilu Pharmaceutical Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
- 6.10.5 Qilu Pharmaceutical Recent Developments
- 6.11 Dr Reddy's Laboratories
- 6.11.1 Dr Reddy's Laboratories Company Information
- 6.11.2 Dr Reddy's Laboratories Business Overview
- 6.11.3 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio
- 6.11.5 Dr Reddy's Laboratories Recent Developments
- 6.12 Debiopharm
- 6.12.1 Debiopharm Company Information
- 6.12.2 Debiopharm Business Overview
- 6.12.3 Debiopharm Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Debiopharm Platinum Anti-tumor Drugs Product Portfolio
- 6.12.5 Debiopharm Recent Developments
- 6.13 ASK Pharma
- 6.13.1 ASK Pharma Company Information
- 6.13.2 ASK Pharma Business Overview
- 6.13.3 ASK Pharma Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 ASK Pharma Platinum Anti-tumor Drugs Product Portfolio
- 6.13.5 ASK Pharma Recent Developments
- 6.14 Accord Healthcare
- 6.14.1 Accord Healthcare Company Information
- 6.14.2 Accord Healthcare Business Overview
- 6.14.3 Accord Healthcare Platinum Anti-tumor Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio
- 6.14.5 Accord Healthcare Recent Developments
7 North America
- 7.1 North America Platinum Anti-tumor Drugs Market Size (2021-2032)
- 7.2 North America Platinum Anti-tumor Drugs Market Size by Type
- 7.2.1 North America Platinum Anti-tumor Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Platinum Anti-tumor Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Platinum Anti-tumor Drugs Market Share by Type (2021-2032)
- 7.3 North America Platinum Anti-tumor Drugs Market Size by Application
- 7.3.1 North America Platinum Anti-tumor Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Platinum Anti-tumor Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Platinum Anti-tumor Drugs Market Share by Application (2021-2032)
- 7.4 North America Platinum Anti-tumor Drugs Market Size by Country
- 7.4.1 North America Platinum Anti-tumor Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Platinum Anti-tumor Drugs Market Size (2021-2032)
- 8.2 Europe Platinum Anti-tumor Drugs Market Size by Type
- 8.2.1 Europe Platinum Anti-tumor Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Platinum Anti-tumor Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Platinum Anti-tumor Drugs Market Share by Type (2021-2032)
- 8.3 Europe Platinum Anti-tumor Drugs Market Size by Application
- 8.3.1 Europe Platinum Anti-tumor Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Platinum Anti-tumor Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Platinum Anti-tumor Drugs Market Share by Application (2021-2032)
- 8.4 Europe Platinum Anti-tumor Drugs Market Size by Country
- 8.4.1 Europe Platinum Anti-tumor Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Platinum Anti-tumor Drugs Market Size (2021-2032)
- 9.2 China Platinum Anti-tumor Drugs Market Size by Type
- 9.2.1 China Platinum Anti-tumor Drugs Market Size by Type (2021-2026)
- 9.2.2 China Platinum Anti-tumor Drugs Market Size by Type (2027-2032)
- 9.2.3 China Platinum Anti-tumor Drugs Market Share by Type (2021-2032)
- 9.3 China Platinum Anti-tumor Drugs Market Size by Application
- 9.3.1 China Platinum Anti-tumor Drugs Market Size by Application (2021-2026)
- 9.3.2 China Platinum Anti-tumor Drugs Market Size by Application (2027-2032)
- 9.3.3 China Platinum Anti-tumor Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Platinum Anti-tumor Drugs Market Size (2021-2032)
- 10.2 Asia Platinum Anti-tumor Drugs Market Size by Type
- 10.2.1 Asia Platinum Anti-tumor Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Platinum Anti-tumor Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Platinum Anti-tumor Drugs Market Share by Type (2021-2032)
- 10.3 Asia Platinum Anti-tumor Drugs Market Size by Application
- 10.3.1 Asia Platinum Anti-tumor Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Platinum Anti-tumor Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Platinum Anti-tumor Drugs Market Share by Application (2021-2032)
- 10.4 Asia Platinum Anti-tumor Drugs Market Size by Country
- 10.4.1 Asia Platinum Anti-tumor Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Platinum Anti-tumor Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst